Objective: To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction (AMI) patients. Methods: The study period was from January 2020 to December 2023, the sample source was 82 AMI patients admitted to our hospital, grouped into an observation group (n = 41) and a control group (n = 41) by the numerical table method. The patients in the control group were treated with aspirin enteric-coated tablets, and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate. The clinical efficacy, coagulation indexes, and the incidence of cardiovascular adverse events between the two groups were compared. Results: The clinical efficacy of the observation group was higher than that of the control group (P < 0.05); the platelet aggregation rate (PAR) of the observation group was lower than that of the control group after treatment (P < 0.05), and there was no significant difference in the prothrombin time (PT) and activated partial thromboplastin time (APTT) between the two groups (P > 0.05). The incidence of cardiovascular adverse events in the observation group was lower than that of the control group (P < 0.05). Conclusion: The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable. It reduces the PAR and the incidence of cardiovascular adverse events, so this treatment method should be popularized.